RxDoctor Payments Data

Kimberly Woods

Family · Statesville, NCNPI 1912427659

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,153 of the $61,948 with a category attached, or 63.2%. 60 manufacturers reported payments, led by Lilly USA, LLC at 45.1% of the total. 2025 is the largest year on record at $32,564, more than ten times the $2,315 reported in 2021. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,948in general payments, 2019–2025

Across 1,170 payments — averaging $52.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$28K
  • AbbVie$15K
  • Inspire Medical Systems, Inc.$2K
  • UCB, Inc.$1K
  • SK Life Science, Inc.$1K
  • Pfizer$1K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$39,15363%
  • Travel & lodging$2,8775%
  • Food & beverage$19,38431%
  • Education$5341%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC92$27,921
AbbVie(2 entities)156$15,483
Inspire Medical Systems, Inc.29$1,782
UCB, Inc.71$1,344
SK Life Science, Inc.55$1,216
Pfizer39$1,070
Teva Pharmaceuticals USA, Inc.66$1,023
Jazz Pharmaceuticals Inc.39$983
MDD US Operations, LLC69$938
Neurelis, Inc.48$899
Acadia Pharmaceuticals Inc31$762
Biogen45$736
Neurocrine Biosciences, Inc.48$695
Axsome Therapeutics, Inc.25$587
Amgen29$537
Eisai Inc.31$530
Lundbeck LLC18$431
Sunovion Pharmaceuticals Inc.27$403
Novartis22$398
Scilex Pharmaceuticals Inc.15$309
Argenx US, Inc.12$297
Sumitomo Pharma America, Inc.12$253
Harmony Biosciences LLC9$237
Upsher-smith Laboratories LLC15$230
Amneal Pharmaceuticals LLC18$229
Sanofi10$220
Aucta Pharmaceuticals, Inc.12$216
Idorsia Pharmaceuticals US Inc15$197
Biohaven Pharmaceutical Holding Company Ltd.14$170
Azurity Pharmaceuticals, Inc.6$153
AstraZeneca(2 entities)8$150
Otsuka America Pharmaceutical, Inc.6$149
Biohaven Pharmaceuticals, Inc.14$141
Avadel CNS Pharmaceuticals, LLC4$107
Impel Pharmaceuticals LLC4$102
Collegium Pharmaceutical, Inc.6$95
Impel Pharmaceuticals Inc.5$95
Almatica Pharma LLC6$93
Boston Scientific3$87
Acorda Therapeutics, Inc5$69
CSL Behring3$63
Supernus Pharmaceuticals, Inc.3$57
Arbor Pharmaceuticals, Inc.3$53
Grifols USA, LLC2$50
ANI Pharmaceuticals, Inc.2$48
Corium, LLC2$40
Mallinckrodt Hospital Products Inc.2$40
Octapharma USA, Inc.1$30
Takeda Pharmaceuticals U.S.A., Inc.1$27
Avanir Pharmaceuticals, Inc.1$22
Insightec,inc1$22
Inogen, Inc.2$22
3b Medical, Inc.1$21
Otsuka Pharmaceutical Development & Commercialization, Inc.1$20
Avion Pharmaceuticals1$19
Sanofi-aventis U.S. LLC1$17
Novo Nordisk1$16
GE HealthCare1$15
Medtronic1$14
Aprecia Pharmaceuticals, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,948 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,481
Medicare patients
204
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant69$106,733
QuliptaAtogepant82$100,964
TrileptalOxcarbazepine13$20,292
Emgality PenGalcanezumab-Gnlm23$15,801
BotoxOnabotulinumtoxina12$15,156
LamictalLamotrigine13$13,718
Emgality SyringeGalcanezumab-Gnlm19$12,796
QuviviqDaridorexant Hcl11$5,089
Gabapentin137$2,331
Doxepin Hcl52$2,120
Sumatriptan Succinate22$1,515
Pregabalin25$1,110
Memantine Hcl48$779
Levetiracetam26$688
Primidone14$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$15,483$222,853163 claims
Idorsia Pharmaceuticals US IncQuviviq$197$5,08911 claims
Upsher-smith Laboratories LLCTopiramate$230$28352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →